I guess they sold some at the end of September- 4,820.
Not sure why they would given that's a pretty insignificant amount (0.35%).
This article came out the other day:
BlackRock Inc. cut its holdings in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 0.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,386,354 shares of the specialty pharmaceutical company’s stock after selling 4,820 shares during the quarter. BlackRock Inc. owned 11.72% of ANI Pharmaceuticals worth $78,384,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Teachers Retirement System of The State of Kentucky increased its holdings in shares of ANI Pharmaceuticals by 99.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock worth $113,000 after purchasing an additional 1,000 shares during the period. Thomson Horstmann & Bryant Inc. increased its holdings in shares of ANI Pharmaceuticals by 5.3% during the third quarter. Thomson Horstmann & Bryant Inc. now owns 25,156 shares of the specialty pharmaceutical company’s stock worth $1,422,000 after purchasing an additional 1,258 shares during the period. Strs Ohio increased its holdings in shares of ANI Pharmaceuticals by 10.7% during the third quarter. Strs Ohio now owns 13,500 shares of the specialty pharmaceutical company’s stock worth $763,000 after purchasing an additional 1,300 shares during the period. Legal & General Group Plc increased its holdings in shares of ANI Pharmaceuticals by 8.0% during the second quarter. Legal & General Group Plc now owns 17,876 shares of the specialty pharmaceutical company’s stock worth $1,198,000 after purchasing an additional 1,318 shares during the period. Finally, Rhumbline Advisers increased its holdings in shares of ANI Pharmaceuticals by 6.8% during the second quarter. Rhumbline Advisers now owns 21,866 shares of the specialty pharmaceutical company’s stock worth $1,461,000 after purchasing an additional 1,399 shares during the period. 63.23% of the stock is currently owned by institutional investors.
-RG
